BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sasso FC, Pafundi PC, Caturano A, Galiero R, Vetrano E, Nevola R, Petta S, Fracanzani AL, Coppola C, Di Marco V, Solano A, Lombardi R, Giordano M, Craxi A, Perrella A, Sardu C, Marfella R, Salvatore T, Adinolfi LE, Rinaldi L. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2021;31:2345-53. [DOI: 10.1016/j.numecd.2021.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Machanahalli Balakrishna A, Ismayl M, Butt DN, Niu F, Latif A, Arouni AJ. Trends, outcomes, and management of acute myocardial infarction in patients with chronic viral hepatitis. Hosp Pract (1995) 2022;:1-8. [PMID: 35483377 DOI: 10.1080/21548331.2022.2072314] [Reference Citation Analysis]